| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vitro |
Ascaridole potently inhibited the in vitro development of Plasmodium falciparum (Gambian isolate FCR3). A 50% reduction in growth rate was observed at a concentration of 1.85 × 10⁻⁸ M, while total growth inhibition occurred at 5.5 × 10⁻⁸ M. At 1.0 × 10⁻⁷ M, parasites were completely eliminated from culture after 3 days. [1]
Stage specificity was observed: at lower concentrations, trophozoites were preferentially inhibited (e.g., at 20 μM ascaridole, 83.6% inhibition of hypoxanthine incorporation in trophozoites on day 1), whereas ring stages were only marginally affected (up to 20.4% inhibition at 20 μM on day 1). However, ring cultures showed increased inhibition at later time points (e.g., at 20 μM, 62.1% inhibition on day 2), indicating that the drug’s target is present but less susceptible in ring stages. [1] Cineol, an analog with an epoxide group instead of the endoperoxide group, showed no antimalarial activity at identical concentrations (e.g., at 60 μM, 98-99% of control hypoxanthine incorporation), demonstrating that the peroxide group is essential for activity. [1] |
|---|---|
| Cell Assay |
Plasmodium falciparum (FCR3 strain) was cultured in human erythrocytes (O⁺) at 5% hematocrit in RPMI 1640 medium with 10% human serum and 25 mM HEPES (pH 7.3) using the candle-jar method. Synchronized cultures at ring or trophozoite stages were obtained by sorbitol treatment. [1]
For drug testing, parasitized erythrocytes were diluted to 0.1%-0.5% parasitemia in 5% non-infected erythrocyte suspension containing the test drug. Aliquots (100 μL) were placed into 96-well microculture trays. Medium was replaced daily with fresh medium containing the appropriate drug. Ascaridole and cineol were initially dissolved in propylene glycol to 0.6 M, then diluted with complete medium to desired concentrations. Propylene glycol alone had no effect on parasite development. [1] Parasite growth was assessed either by Giemsa-stained smears or by [³H]-hypoxanthine incorporation. For the latter, 5 μCi [³H]-hypoxanthine (10 Ci/mmol) was added at indicated times (20 h or 40 h after drug removal), cells were harvested 18 h later onto filters, and incorporation was measured by liquid scintillation counting. Each experiment was repeated in triplicate. [1] |
| References | |
| Additional Infomation |
Ascaridole is a p-menthane monoterpene with the structure p-menthane-2-ene, with a peroxide group attached at positions 1 to 4. It is used as an anti-nematode agent, a plant metabolite, and an anti-leishmaniasis agent. It is a p-menthane monoterpene, an organic peroxide, and an organic heterobicyclic compound. Ascaridole has been reported in Zanthoxylum schinifolium, Achillea biebersteinii, and other organisms with relevant data. See also: Peumus boldus (partial); Dysphania ambrosioides (whole plant) (partial).
Ascaridole is a terpene isolated from the plant Chenopodium ambrosioides (American wormseed). It contains an endoperoxide group structurally similar to artemisinin, which is responsible for its antimalarial activity. Ascaridole has been used conventionally as an anthelmintic. [1] The peroxide group is essential for antimalarial activity, as the epoxide-containing analog cineol was inactive. Dihydroascaridole (which retains the peroxide but lacks the double bond) has been reported elsewhere to have EC₅₀ values of 0.21 μM (chloroquine-resistant) and 0.08 μM (chloroquine-sensitive) P. falciparum in vitro, but this is from another study (Vennerstrom and Eaton 1988), not tested in this paper. [1] |
| Molecular Formula |
C10H16O2
|
|---|---|
| Molecular Weight |
168.23
|
| Exact Mass |
168.115
|
| CAS # |
512-85-6
|
| Related CAS # |
1354425-86-7; 512-85-6;
|
| PubChem CID |
10545
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.051 g/cm3
|
| Boiling Point |
172.3ºC at 760 mmHg
|
| Melting Point |
3.3ºC
|
| Flash Point |
55.9ºC
|
| Index of Refraction |
1.498
|
| LogP |
2.451
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)C12CCC(C=C1)(OO2)C
|
| InChi Key |
MGYMHQJELJYRQS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H16O2/c1-8(2)10-6-4-9(3,5-7-10)11-12-10/h4,6,8H,5,7H2,1-3H3
|
| Chemical Name |
1-methyl-4-propan-2-yl-2,3-dioxabicyclo[2.2.2]oct-5-ene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~594.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9442 mL | 29.7212 mL | 59.4424 mL | |
| 5 mM | 1.1888 mL | 5.9442 mL | 11.8885 mL | |
| 10 mM | 0.5944 mL | 2.9721 mL | 5.9442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
